Dublin and Munich-based LUMA Vision, a developer of a novel four-dimensional (4D) cardiac imaging and navigation platform, announced that it has secured €20m in a Series A3 funding round led by existing investors EQT Lifesciences, ABV Uni Fund, and imec.xpand.
The new funding adds to prestigious grants won earlier by LUMA Vision from the Irish government’s Disruptive Technologies Innovation Fund and the European Union’s EIC Accelerator.
LUMA Vision CEO Fionn Lahart says, “we are delighted to welcome to the company our new investors and gratified to secure the continued backing of our highly regarded existing investors. As a truly pan-European startup with offices in Dublin and Munich, we have grown our team significantly in the last three years and will continue to add world-class talent to help LUMA Vision achieve its goals.”
The Irish company will use the new funds to gain FDA clearance, prepare for US commercialisation and develop the next generations of its VERAFEYE platform for additional clinical applications in cardiology and beyond.
Founded by Fionn Lahart (CEO) and Christoph Hennersperger (CTO), LUMA Vision (formerly known as OneProjects Ltd) is a medical device company that designs and develops an innovative 4D imaging and navigation end-to-end platform — VERAFEYE for cardiology.
The technology uses a proprietary catheter sensor combined with advanced digital imaging and deep learning to provide unprecedented, high-resolution, 360-degree imagery of the beating heart and surrounding anatomy.
VERAFEYE is a versatile tool that can be used alongside other catheters or systems during cardiac surgery.
With its multiple applications, VERAFEYE offers real-time imaging guidance that eliminates the need for external systems such as X-ray or CT.
This makes VERAFEYE a comprehensive platform that can provide all the imaging assistance required during cardiac surgery.
According to the company, this technology will provide cardiologists with accurate, precise, and comprehensive anatomical data required to guide personalised patient therapy across a variety of diseases, such as atrial fibrillation, left atrial appendage closure, and cardiac valve replacement.
Lahart said, “physicians require accurate, real-time data at the point of care to effectively treat patients. Our goal with VERAFEYE is to provide the data and imaging physicians need in one system to successfully treat as many of the conditions their patients face as possible. By developing a technology platform that can be tailored for specific therapies in cardiology, we believe that VERAFEYE can be a bedrock of medical imaging for many years to come.”
Professor Gabor Szlepaki, Head of Cardiac Electrophysiology at the Mater Private Hospital Dublin and Centre Clinical lead of the Atrial Fibrillation Institute, adds, “this new technology has the potential to help us deliver more precise therapies for patients suffering from abnormal heart rhythms or structural heart problems. This type of medical innovation is essential for the continuous progression of minimally invasive cardiac therapies that can improve patient care.”
Source: Silicon Canals
